21 U.S.C. § §360ee–1. FDA rare neurodegenerative dis — §360ee–1. FDA rare neurodegenerative disease grant program

FEDERAL · 21 U.S.C. · Chapter SUBCHAPTER V—DRUGS AND DEVICES

§360ee–1. FDA rare neurodegenerative disease grant program

21 U.S.C. § §360ee–1. FDA rare neurodegenerative dis

ChapterSUBCHAPTER V—DRUGS AND DEVICES

PartB

This text of 21 U.S.C. § §360ee–1. FDA rare neurodegenerative dis (§360ee–1. FDA rare neurodegenerative disease grant program) is published on Counsel Stack Legal Research, covering United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

21 U.S.C. § §360ee–1. FDA rare neurodegenerative dis.

Text

The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—

(1)to characterize such neurodegenerative diseases and their natural history;

(2)to identify molecular targets for such neurodegenerative diseases; and

(3)to increase efficiency and productivity of clinical development of therapies, including through—

(A)the use of master protocols and adaptive and a

Free access — add to your briefcase to read the full text and ask questions with AI

The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—
(1) to characterize such neurodegenerative diseases and their natural history;
(2) to identify molecular targets for such neurodegenerative diseases; and
(3) to increase efficiency and productivity of clinical development of therapies, including through—
(A) the use of master protocols and adaptive and add-on clinical trial designs; and
(B) efforts to establish new or leverage existing clinical trial networks.

Source Credit

History

(Pub. L. 117–79, §5, Dec. 23, 2021, 135 Stat. 1537.)

Editorial Notes

Editorial Notes

Codification
Section was enacted as part of the Accelerating Access to Critical Therapies for ALS Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

Cite This Page — Counsel Stack

Bluebook (online)

21 U.S.C. § §360ee–1. FDA rare neurodegenerative dis, Counsel Stack Legal Research, https://law.counselstack.com/usc/21/§360ee–1. FDA rare neurodegenerative dis.